Trade Curis, Inc. - CRIS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.2848 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 6.0476 |
| Open | 6.1676 |
| 1-Year Change | 1185.18% |
| Day's Range | 5.8476 - 6.1676 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 17, 2024 | 6.0476 | 0.3500 | 6.14% | 5.6976 | 6.2976 | 5.6376 |
| Sep 16, 2024 | 5.7376 | 0.5200 | 9.97% | 5.2176 | 5.8376 | 5.1976 |
| Sep 13, 2024 | 5.3376 | 0.4400 | 8.98% | 4.8976 | 5.3376 | 4.8976 |
| Sep 12, 2024 | 4.9276 | 0.0300 | 0.61% | 4.8976 | 4.9976 | 4.8876 |
| Sep 11, 2024 | 4.9176 | -0.1100 | -2.19% | 5.0276 | 5.0676 | 4.7976 |
| Sep 10, 2024 | 4.8286 | 0.0600 | 1.26% | 4.7686 | 5.0486 | 4.7286 |
| Sep 9, 2024 | 4.7886 | -0.0800 | -1.64% | 4.8686 | 4.8686 | 4.6686 |
| Sep 6, 2024 | 4.7986 | -0.2800 | -5.51% | 5.0786 | 5.0886 | 4.7586 |
| Sep 5, 2024 | 4.9586 | -0.0700 | -1.39% | 5.0286 | 5.1186 | 4.9186 |
| Sep 4, 2024 | 5.0486 | 0.1100 | 2.23% | 4.9386 | 5.1986 | 4.7586 |
| Sep 3, 2024 | 5.1886 | -0.2300 | -4.24% | 5.4186 | 5.5786 | 5.1786 |
| Aug 30, 2024 | 5.2886 | -0.1400 | -2.58% | 5.4286 | 5.6586 | 5.0986 |
| Aug 29, 2024 | 5.3486 | -0.1200 | -2.19% | 5.4686 | 5.6986 | 5.2986 |
| Aug 28, 2024 | 5.6186 | -0.4400 | -7.26% | 6.0586 | 6.0586 | 5.4986 |
| Aug 27, 2024 | 5.9186 | -0.3000 | -4.82% | 6.2186 | 6.3386 | 5.9186 |
| Aug 26, 2024 | 6.1086 | 0.0700 | 1.16% | 6.0386 | 6.3786 | 5.8286 |
| Aug 23, 2024 | 6.0086 | -0.1800 | -2.91% | 6.1886 | 6.2886 | 5.7486 |
| Aug 22, 2024 | 5.7486 | -0.6700 | -10.44% | 6.4186 | 8.2186 | 5.7486 |
| Aug 21, 2024 | 5.9286 | 1.5300 | 34.78% | 4.3986 | 6.3486 | 4.3286 |
| Aug 20, 2024 | 4.2986 | 0.1000 | 2.38% | 4.1986 | 4.3186 | 4.1986 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Curis, Inc. Company profile
About Curis, Inc.
Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-arm dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Curis, Inc. revenues decreased 2% to $10.6M. Net loss increased 52% to $45.4M. Revenues reflect Other revenue decrease of 100% to $1K. Higher net loss reflects Research & development Expenses B/F increase of 50% to $32M (expense), Other General and administrative, increase of 43% to $8M (expense), General and administrative expenses increase of 75% to $3.4M (expense).
Equity composition
Common Stock $.01 Par, 03/11, 125M auth., 77,397,663 issd., less 1,047,707 shs. in tres. @ $891K. Insiders own 2.72%. IPO 12/92, 3M shs. @ $7 by Montgomery Secs. *8/00, Co.merged with Ontogeny & Reprogenesis & chgd. name from Creative Biomolecules, Inc. FY'03&'04 are RES-Acct. Change. Summ. Qs reflects RES.
| Industry: | Biotechnology & Medical Research (NEC) |
128 Spring Street
4 Maguire Road
LEXINGTON
MASSACHUSETTS 02421
US
News
Bank of Japan Preview
The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.
09:40, 17 September 2024
FOMC Decision Preview
As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.
09:48, 16 September 2024
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com